share_log

復星醫藥：(1)以吸收合併復宏漢霖之方式由復星新藥對復宏漢霖私有化之建議(2)建議撤銷復宏漢霖H股上市(3)臨時股東大會通告及(4)H股類別股東大會通告

FOSUN PHARMA: (1) PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS (2) PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF HENLIUS (3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING AND (4) NOTICE OF THE H SHAREHOLDERS' CLASS

HKEX ·  Dec 22 18:30

Summary by Moomoo AI

上海復星新藥研究有限公司擬以每股24.60港元的價格私有化上海復宏漢霖生物技術股份有限公司。該方案提供現金選擇權和股份選擇權（上限為已發行股份總數的8%）。非上市股份的註銷價為每股人民幣22.444794元。獨立董事委員會建議股東投票贊成該合併方案。H股類別股東大會將於2025年1月22日舉行，採用投票表決方式。除要約人及其一致行動人士外，所有H股持有人均有資格參與投票。股東可委任一名或多名代理人，代理人委任表格須於會議前24小時（即2025年1月21日下午2:30前）提交。H股過戶登記將於2025年1月17日至22日期間暫停。重要日期包括：H股登記截止日期為2025年1月16日下午4:30；臨時股東大會和H股類別股東大會於2025年1月22日舉行；選擇表格提交截止日期為2025年2月28日；最後截止日期為2025年4月30日。股東需自行承擔參會的交通和住宿費用。所有提及的日期和時間均為北京時間。
上海復星新藥研究有限公司擬以每股24.60港元的價格私有化上海復宏漢霖生物技術股份有限公司。該方案提供現金選擇權和股份選擇權（上限為已發行股份總數的8%）。非上市股份的註銷價為每股人民幣22.444794元。獨立董事委員會建議股東投票贊成該合併方案。H股類別股東大會將於2025年1月22日舉行，採用投票表決方式。除要約人及其一致行動人士外，所有H股持有人均有資格參與投票。股東可委任一名或多名代理人，代理人委任表格須於會議前24小時（即2025年1月21日下午2:30前）提交。H股過戶登記將於2025年1月17日至22日期間暫停。重要日期包括：H股登記截止日期為2025年1月16日下午4:30；臨時股東大會和H股類別股東大會於2025年1月22日舉行；選擇表格提交截止日期為2025年2月28日；最後截止日期為2025年4月30日。股東需自行承擔參會的交通和住宿費用。所有提及的日期和時間均為北京時間。
Shanghai Fosun Pharmaceutical Research Co., Ltd. plans to privatize Shanghai HENLIUS Biotechnology Co., Ltd. at a price of HKD 24.60 per share. The proposal offers cash options and share options (capped at 8% of the total issued shares). The cancellation price for non-listed shares is RMB 22.444794 per share. The independent director committee recommends shareholders to vote in favor of the merger proposal.The H shares class shareholders meeting will be held on January 22, 2025, using a voting ballot. All H share holders, except the offeror and its concert parties, are eligible to participate in the voting. Shareholders may appoint one or more agents, and the agent appointment forms must be submitted 24 hours prior to the meeting (by 2:30 PM on January 21, 2025). H share...Show More
Shanghai Fosun Pharmaceutical Research Co., Ltd. plans to privatize Shanghai HENLIUS Biotechnology Co., Ltd. at a price of HKD 24.60 per share. The proposal offers cash options and share options (capped at 8% of the total issued shares). The cancellation price for non-listed shares is RMB 22.444794 per share. The independent director committee recommends shareholders to vote in favor of the merger proposal.The H shares class shareholders meeting will be held on January 22, 2025, using a voting ballot. All H share holders, except the offeror and its concert parties, are eligible to participate in the voting. Shareholders may appoint one or more agents, and the agent appointment forms must be submitted 24 hours prior to the meeting (by 2:30 PM on January 21, 2025). H share transfer registration will be suspended from January 17 to 22, 2025.Important dates include: the H share registration deadline is January 16, 2025, at 4:30 PM; the extraordinary general meeting and H shares class shareholders meeting will be held on January 22, 2025; the deadline for submitting selection forms is February 28, 2025; the final deadline is April 30, 2025. Shareholders will need to bear their own transportation and lodging expenses for attending the meeting. All mentioned dates and times are in Peking time.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated